Search Result

Results for "

T2D

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Adrenergic Receptor (1) AMPK (1) Amylin Receptor (1) Biochemical Assay Reagents (1) Endogenous Metabolite (6) FBPase (1) GCGR (5) GLP Receptor (4) Glucokinase (2) Glycosidase (1) Histone Acetyltransferase (1) Liposome (2) Reactive Oxygen Species (1)
By Research Areas:	Cardiovascular Disease (1) Inflammation/Immunology (2) Metabolic Disease (27) Neurological Disease (1)
Oligonucleotides:	Pegylated Lipids (1) Liposomal Film-forming Agents (1) Emulsifiers (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) ^[2] .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) ^[2] .

HY-146725

FBPase-IN-1	FBPase	Metabolic Disease
FBPase-IN-1 is a potent FBPase (Fructose-1,6-bisphosphatase) inhibitor for Type 2 diabetes (T2D) study with an IC₅₀ of 0.22 μM. FBPase-IN-1 can reduce blood glucose levels and ameliorate glucose tolerance. FBPase-IN-1 modifies the C128 site, regulates the N125-S124-S123 allosteric pathway of FBPase and affects the catalytic activity of FBPase .

HY-P0120

Dulaglutide 1 Publications Verification LY2189265	GCGR	Metabolic Disease
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) ^[2].

HY-139284

C24:1 Dihydro 1-deoxyceramide (m18:0/24:1) C24:1 Deoxy dihydroceramide; C24:1 DeoxyDHceramide; Cer(m18:0/24:1)	Endogenous Metabolite	Metabolic Disease
C24:1 Dihydro 1-deoxyceramide (m18:0/24:1) (C24:1 Deoxy dihydroceramide) is a lipid molecule, which is composed of a long-chain fatty acid (24:1) and a 1-deoxysphingoid backbone. Deoxyceramide accumulates under the conditions of obesity and type 2 diabetes (T2D). Deoxyceramide is unable to be further metabolized to more complex sphingolipid, and is toxic when accumulates in the body. Deoxyceramide increases in differentiated adipocytes in vitro .

HY-139282

C16 1-Deoxyceramide (m18:1/16:0) C16:0 1-Deoxyceramide; C16:0 Ceramide (m18:1/16:0); Cer(m18:1/16:0)	Endogenous Metabolite	Metabolic Disease
C16 1-Deoxyceramide (m18:1/16:0) (C16:0 1-Deoxyceramide) is a lipid molecule, which is composed of a long-chain fatty acid (16:0) and a 1-deoxysphingoid backbone. Deoxyceramide accumulates under the conditions of obesity and type 2 diabetes (T2D). Deoxyceramide is unable to be further metabolized to more complex sphingolipid, and is toxic when accumulates in the body. Deoxyceramide increases in differentiated adipocytes in vitro .

HY-121070

AZD1092	Glucokinase	Metabolic Disease
AZD1092 is an orally active glucokinase (GK) activator with an EC₅₀ value of 0.03 μM. AZD1092 can be used for the research of Type 2 Diabetes (T2D) .

HY-116946

Glucokinase activator 6	Glucokinase	Metabolic Disease
Glucokinase activator 6 (compound 9) is a potent glucokinase activator, with an EC₅₀ of 0.09 μM. Glucokinase activator 6 can be used for type 2 diabetes (T2D) research .

HY-114566

SPV106	Histone Acetyltransferase	Metabolic Disease
SPV106 is histone acetylase (HAT) and GCN5-related N-acetyltransferases (GNAT) activator. SPV106 can be used for the research of type 2 diabetes (T2D) .

HY-139283

C24:1 1-Deoxyceramide (m18:1/24:1(15Z)) C24:1(15Z) 1-Deoxyceramide; C24:1 Ceramide (m18:1/24:1(15Z)); Cer(m18:1/24:1(15Z))	Endogenous Metabolite	Metabolic Disease
C24:1 1-Deoxyceramide (m18:1/24:1(15Z)) (C24:1(15Z) 1-Deoxyceramide) is a lipid molecule, which is composed of a long-chain fatty acid (24:1) and a 1-deoxysphingoid backbone. Deoxyceramide accumulates under the conditions of obesity and type 2 diabetes (T2D). Deoxyceramide is unable to be further metabolized to more complex sphingolipid, and is toxic when accumulates in the body. Deoxyceramide increases in differentiated adipocytes in vitro .

HY-149727

β2AR agonist 2	Adrenergic Receptor	Metabolic Disease
β2AR agonist 2(compound 8a) is a β₂ -Adrenergic receptor (β₂AR) agonist. β2AR agonist 2 is a saturated nitrogen ring compound containing 4- to 7-membered heterocycle. β2AR agonist 2 has a chiral structure (the -R form) by carrying carbon containing the essential hydroxyl, thereby enhancing cellular glucose uptake (GU) activity and significantly stimulating glucose uptake by skeletal muscle cells. β2AR agonist 2 can be used in the study of Type 2 Diabetes (T2D) .

HY-112233

O-304 4 Publications Verification	AMPK	Cardiovascular Disease Metabolic Disease
O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a agent to treat type 2 diabetes (T2D) and associated cardiovascular complications ^[2].

HY-P5878

RG33 Peptide	Biochemical Assay Reagents	Metabolic Disease
RG33 Peptide is a diabetes inhibitor that significantly improves glucose clearance in insulin-resistant mice. RG33 Peptide effectively solubilizes lipid vesicles and promotes cholesterol efflux in cultured macrophages. RG33 Peptide is used in research into type 2 diabetes (T2D) .

HY-P4767

Amylin (1-13) (human)	Amylin Receptor	Metabolic Disease
Amylin (1-13) (human) is a fragment and a residues within amyloid cores of Amylin (human IAPP). Amylin is a glucose-regulating hormone, deposits as amyloid fibrils in condition of type II diabetes (T2D). Amylin (1-13) (human) has no effect on firbl formation, as it cannot form fibrils by itself .

HY-108795

Albiglutide fragment GLP-1-Gly8; GLP-1 (7-36) analog	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies ^[2] .

HY-108795A

Albiglutide fragment TFA GLP-1-Gly8 TFA; GLP-1 (7-36) analog TFA	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies ^[2] .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) ^[2] .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) ^[2] .

HY-W015229R

3-Indolepropionic acid (Standard)	Endogenous Metabolite Reactive Oxygen Species	Neurological Disease Metabolic Disease
3-Indolepropionic acid (Standard) is the analytical standard of 3-Indolepropionic acid. This product is intended for research and analytical applications. 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease. In Vitro: 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease . 3-Indolepropionic acid is a more potent scavenger of hydroxyl radicals than melatonin. Similar to melatonin but unlike other antioxidants, 3-Indolepropionic acid scavenges radicals without subsequently generating reactive and pro-oxidant intermediate compounds ^[2]. It is also suggested that indolepropionic acid, a gut microbiota-produced metabolite, is a potential biomarker for the development of type 2 diabetes (T2D) that may mediate its protective effect by preservation of β-cell function .

HY-18057

BVT-3498 AMG-311	11β-HSD	Metabolic Disease
BVT-3498 (AMG-311) is an inhibitor for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) .

HY-W709961

5-OAHSA 1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
5-OAHSA (1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate) is a endogenous lipid. 5-OAHSA reduces the level of blood glucose, improves the glucose tolerance, and stimulates the the secretion of GLP-1 and insulin. 5-OAHSA exhibits potential in regulating metabolic and inflammatory responses .

HY-169411

α-Glucosidase-IN-77	Glycosidase	Metabolic Disease
α-Glucosidase-IN-77 (Compound H7) is a non-competitive inhibitor for α-glucosidase with an IC₅₀ of 1.25 μM. α-Glucosidase-IN-77 lowers blood glucose levels, improves glucose tolerance, regulates intestinal microbiota, and exhibits hepatoprotective effect in mouse type 2 diabetes model .

HY-113381

2-Hydroxybutyric acid 1 Publications Verification α-Hydroxybutyric acid	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
2-Hydroxybutyric acid (α-Hydroxybutyric acid ) is converted from 2-Aminobutyric acid, with 2-oxobutyric acid as an intermediate metabolite . 2-Hydroxybutyric acid is a potential biomarker for type 2 diabetes and preeclampsia ^[2] . 2-Hydroxybutyric acid prevents the acetaminophen (AP)-induced liver injury .

HY-112764

DMG-PEG 2000 Maximum Cited Publications 8 Publications Verification	Liposome	Metabolic Disease
DMG-PEG 2000 is used?for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the?lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .

HY-112764A

DMG-PEG (Excipient)	Liposome	Metabolic Disease
DMG-PEG Excipient is used?for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG Excipient is also used for the?lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library	837 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 837 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Anti-diabetic Compound Library

837 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 837 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Type

HY-112764

DMG-PEG 2000 5+ Cited Publications	Drug Delivery
DMG-PEG 2000 is used?for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the?lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .

Cat. No.	Product Name	Target	Research Area

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) ^[2] .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) ^[2] .

HY-P0120

Dulaglutide 1 Publications Verification LY2189265	GCGR	Metabolic Disease
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) ^[2].

HY-108795A

Albiglutide fragment TFA GLP-1-Gly8 TFA; GLP-1 (7-36) analog TFA	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies ^[2] .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) ^[2] .

HY-P5878

RG33 Peptide	Biochemical Assay Reagents	Metabolic Disease
RG33 Peptide is a diabetes inhibitor that significantly improves glucose clearance in insulin-resistant mice. RG33 Peptide effectively solubilizes lipid vesicles and promotes cholesterol efflux in cultured macrophages. RG33 Peptide is used in research into type 2 diabetes (T2D) .

HY-P4767

Amylin (1-13) (human)	Amylin Receptor	Metabolic Disease
Amylin (1-13) (human) is a fragment and a residues within amyloid cores of Amylin (human IAPP). Amylin is a glucose-regulating hormone, deposits as amyloid fibrils in condition of type II diabetes (T2D). Amylin (1-13) (human) has no effect on firbl formation, as it cannot form fibrils by itself .

HY-108795

Albiglutide fragment GLP-1-Gly8; GLP-1 (7-36) analog	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies ^[2] .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) ^[2] .

HY-112431

Carnostatine SAN9812	Peptides	Metabolic Disease
Carnostatine (SAN9812) is a potent and selective carnosinase 1 (CN1) inhibitor with a K_i of 11 nM for human recombinant CN1. Carnostatine (SAN9812) can be used for the treatment of diabetic nephropathy (DN) .

HY-112431A

Carnostatine hydrochloride SAN9812 hydrochloride	Peptides	Metabolic Disease
Carnostatine hydrochloride (SAN9812 hydrochloride) is a potent and selective carnosinase 1 (CN1) inhibitor with a K_i of 11 nM for human recombinant CN1. Carnostatine hydrochloride can be used for the treatment of diabetic nephropathy (DN) .

2-Hydroxybutyric acid 1 Publications Verification α-Hydroxybutyric acid	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease markers Endocrine diseases Metabolic Disease Endogenous metabolite Disease Research Fields Cardiovascular System Disorder	Endogenous Metabolite
2-Hydroxybutyric acid (α-Hydroxybutyric acid ) is converted from 2-Aminobutyric acid, with 2-oxobutyric acid as an intermediate metabolite . 2-Hydroxybutyric acid is a potential biomarker for type 2 diabetes and preeclampsia ^[2] . 2-Hydroxybutyric acid prevents the acetaminophen (AP)-induced liver injury .

3-Indolepropionic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite Reactive Oxygen Species
3-Indolepropionic acid (Standard) is the analytical standard of 3-Indolepropionic acid. This product is intended for research and analytical applications. 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease. In Vitro: 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease . 3-Indolepropionic acid is a more potent scavenger of hydroxyl radicals than melatonin. Similar to melatonin but unlike other antioxidants, 3-Indolepropionic acid scavenges radicals without subsequently generating reactive and pro-oxidant intermediate compounds ^[2]. It is also suggested that indolepropionic acid, a gut microbiota-produced metabolite, is a potential biomarker for the development of type 2 diabetes (T2D) that may mediate its protective effect by preservation of β-cell function .

Cat. No.	Product Name		Classification

HY-112764

DMG-PEG 2000 5+ Cited Publications		Pegylated Lipids
DMG-PEG 2000 is used?for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the?lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .

HY-112764A

DMG-PEG (Excipient)		Emulsifiers Liposomal Film-forming Agents
DMG-PEG Excipient is used?for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG Excipient is also used for the?lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

T2D

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Oligonucleotides

Natural
Products